Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer

References

• Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411:380 - 4; http://dx.doi.org/10.1038/35077246; PMID: 11357146
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909 - 15; http://dx.doi.org/10.1038/nm1100; PMID: 15340416
   PubMed Web of Science ®Google Scholar
• Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003; 30:843 - 52; http://dx.doi.org/10.1016/S0094-0143(03)00056-9; PMID: 14680319
   PubMed Web of Science ®Google Scholar
• Fournier P, Schirrmacher V. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008. Expert Rev Vaccines 2009; 8:51 - 66; http://dx.doi.org/10.1586/14760584.8.1.51; PMID: 19093773
   PubMed Web of Science ®Google Scholar
• Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D. Part I: Vaccines for solid tumours. Lancet Oncol 2004; 5:681 - 9; http://dx.doi.org/10.1016/S1470-2045(04)01610-9; PMID: 15522656
   PubMed Web of Science ®Google Scholar
• de Gruijl TD, van den Eertwegh AJM, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother 2008; 57:1569 - 77; http://dx.doi.org/10.1007/s00262-008-0536-z; PMID: 18523771
   PubMed Web of Science ®Google Scholar
• Sobol RE. The rationale for prophylactic cancer vaccines and need for a paradigm shift. Cancer Gene Ther 2006; 13:725 - 31; http://dx.doi.org/10.1038/sj.cgt.7700950; PMID: 16543919
   PubMed Web of Science ®Google Scholar
• Pardoll DM. Cancer vaccines. Nat Med 1998; 4:Suppl 525 - 31; http://dx.doi.org/10.1038/nm0598supp-525; PMID: 9585204
   PubMed Web of Science ®Google Scholar
• Westermann J, Flörcken A, Willimsky G, van Lessen A, Kopp J, Takvorian A, et al. Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study. Gene Ther 2011; 18:354 - 63; http://dx.doi.org/10.1038/gt.2010.143; PMID: 21068778
   PubMed Web of Science ®Google Scholar
• Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137:1142 - 62; http://dx.doi.org/10.1084/jem.137.5.1142; PMID: 4573839
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245 - 52; http://dx.doi.org/10.1038/32588; PMID: 9521319
   PubMed Web of Science ®Google Scholar
• Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001; 106:271 - 4; http://dx.doi.org/10.1016/S0092-8674(01)00448-2; PMID: 11509176
   PubMed Web of Science ®Google Scholar
• Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115:3623 - 33; http://dx.doi.org/10.1172/JCI25947; PMID: 16308572
   PubMed Web of Science ®Google Scholar
• Wierecky J, Müller MR, Wirths S, Halder-Oehler E, Dörfel D, Schmidt SM, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006; 66:5910 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-05-3905; PMID: 16740731
   PubMed Web of Science ®Google Scholar
• Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC, Völler MC, De Weijer K, Mulders PF, et al. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J Immunother 2007; 30:116 - 22; http://dx.doi.org/10.1097/01.cji.0000211318.22902.ec; PMID: 17198090
   PubMed Web of Science ®Google Scholar
• Höltl L, Zelle-Rieser C, Gander H, Papesh C, Ramoner R, Bartsch G, et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 2002; 8:3369 - 76; PMID: 12429623
   PubMed Web of Science ®Google Scholar
• Märten A, Flieger D, Renoth S, Weineck S, Albers P, Compes M, et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother 2002; 51:637 - 44; http://dx.doi.org/10.1007/s00262-002-0324-0; PMID: 12439609
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee Y, Bae YS, Kim WS, Kim K, Im HY, et al. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol 2007; 125:257 - 67; http://dx.doi.org/10.1016/j.clim.2007.07.014; PMID: 17916447
   PubMed Web of Science ®Google Scholar
• Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 2007; 30:749 - 61; http://dx.doi.org/10.1097/CJI.0b013e3180de4ce8; PMID: 17893567
   PubMed Web of Science ®Google Scholar
• Barbuto JA, Ensina LF, Neves AR, Bergami-Santos P, Leite KR, Marques R, et al. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol Immunother 2004; 53:1111 - 8; http://dx.doi.org/10.1007/s00262-004-0551-7; PMID: 15185011
   PubMed Web of Science ®Google Scholar
• Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004; 10:4699 - 708; http://dx.doi.org/10.1158/1078-0432.CCR-04-0347; PMID: 15269142
   PubMed Web of Science ®Google Scholar
• Märten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 2003; 14:483 - 94; http://dx.doi.org/10.1089/104303403321467243; PMID: 12691613
   PubMed Web of Science ®Google Scholar
• Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172:1217 - 24; http://dx.doi.org/10.1084/jem.172.4.1217; PMID: 2212951
   PubMed Web of Science ®Google Scholar
• Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13:688 - 96; PMID: 7884429
   PubMed Web of Science ®Google Scholar
• Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996; 14:2410 - 1; PMID: 8708739
   PubMed Web of Science ®Google Scholar
• Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d’Immunothérapie. N Engl J Med 1998; 338:1272 - 8; http://dx.doi.org/10.1056/NEJM199804303381805; PMID: 9562581
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20:289 - 96; http://dx.doi.org/10.1200/JCO.20.1.289; PMID: 11773181
   PubMed Web of Science ®Google Scholar
• Nencioni A, Grünebach F, Schmidt SM, Müller MR, Boy D, Patrone F, et al. The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol 2008; 65:191 - 9; http://dx.doi.org/10.1016/j.critrevonc.2007.10.002; PMID: 18055210
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646 - 74; http://dx.doi.org/10.1016/j.cell.2011.02.013; PMID: 21376230
   PubMed Web of Science ®Google Scholar
• Draube A, Klein-González N, Mattheus S, Brillant C, Hellmich M, Engert A, et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One 2011; 6:e18801; http://dx.doi.org/10.1371/journal.pone.0018801; PMID: 21533099
   PubMed Web of Science ®Google Scholar
• Höltl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, Papesh C, et al. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 2005; 54:663 - 70; http://dx.doi.org/10.1007/s00262-004-0629-2; PMID: 15918076
   PubMed Web of Science ®Google Scholar
• Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJ, Jongmans W, Adema GJ, et al. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother 2002; 25:500 - 8; http://dx.doi.org/10.1097/00002371-200211000-00006; PMID: 12439347
   PubMed Web of Science ®Google Scholar
• Zhou J, Weng D, Zhou F, Pan K, Song H, Wang Q, et al. Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses. Cancer Immunol Immunother 2009; 58:1587 - 97; http://dx.doi.org/10.1007/s00262-009-0668-9; PMID: 19221746
   PubMed Web of Science ®Google Scholar
• Ranieri E, Gigante M, Storkus WJ, Gesualdo L. Translational mini-review series on vaccines: Dendritic cell-based vaccines in renal cancer. Clin Exp Immunol 2007; 147:395 - 400; http://dx.doi.org/10.1111/j.1365-2249.2006.03305.x; PMID: 17302887
   PubMed Web of Science ®Google Scholar
• Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmüller G, et al. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 1993; 151:4209 - 20; PMID: 8409397
   PubMed Web of Science ®Google Scholar
• Frankenberger B, Pohla H, Noessner E, Willimsky G, Papier B, Pezzutto A, et al. Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs. Clin Cancer Res 2005; 11:1733 - 42; http://dx.doi.org/10.1158/1078-0432.CCR-04-1883; PMID: 15755994
   PubMed Web of Science ®Google Scholar
• Malyguine AM, Strobl SL, Shurin MR. Immunological monitoring of the tumor immunoenvironment for clinical trials. Cancer Immunol Immunother 2012; 61:239 - 47; http://dx.doi.org/10.1007/s00262-011-1148-6; PMID: 22080408
   PubMed Web of Science ®Google Scholar
• Kalinski P, Edington H, Zeh HJ, Okada H, Butterfield LH, Kirkwood JM, et al. Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?. Immunol Res 2011; 50:235 - 47; http://dx.doi.org/10.1007/s12026-011-8224-z; PMID: 21717071
   PubMed Web of Science ®Google Scholar
• Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with alpha-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011; 29:330 - 6; http://dx.doi.org/10.1200/JCO.2010.30.7744; PMID: 21149657
   PubMed Web of Science ®Google Scholar
• Spranger S, Javorovic M, Bürdek M, Wilde S, Mosetter B, Tippmer S, et al. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol 2010; 185:738 - 47; http://dx.doi.org/10.4049/jimmunol.1000060; PMID: 20511554
   PubMed Web of Science ®Google Scholar
• Zobywalski A, Javorovic M, Frankenberger B, Pohla H, Kremmer E, Bigalke I, et al. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med 2007; 5:18; http://dx.doi.org/10.1186/1479-5876-5-18; PMID: 17430585
   PubMed Web of Science ®Google Scholar
• Buchner A, Pohla H, Willimsky G, Frankenberger B, Frank R, Baur-Melnyk A, et al. Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma. Hum Gene Ther 2010; 21:285 - 97; http://dx.doi.org/10.1089/hum.2008.192; PMID: 19788391
   PubMed Web of Science ®Google Scholar
• Westermann J, Kopp J, van Lessen A, Hecker AC, Baskaynak G, le Coutre P, et al. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia. Br J Haematol 2007; 137:297 - 306; http://dx.doi.org/10.1111/j.1365-2141.2007.06547.x; PMID: 17408402
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205 - 16; http://dx.doi.org/10.1093/jnci/92.3.205; PMID: 10655437
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, Patard JJ, et al, European Association of Urology Guideline Group for renal cell carcinoma. Renal cell carcinoma guideline. Eur Urol 2007; 51:1502 - 10; http://dx.doi.org/10.1016/j.eururo.2007.03.035; PMID: 17408850
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, et al, European Association of Urology Guideline Group. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010; 58:398 - 406; http://dx.doi.org/10.1016/j.eururo.2010.06.032; PMID: 20633979
   PubMed Web of Science ®Google Scholar
• Escudier B, Kataja V, ESMO Guidelines Working Group. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21:Suppl 5 v137 - 9; http://dx.doi.org/10.1093/annonc/mdq206; PMID: 20555064
   PubMed Web of Science ®Google Scholar
• Brill TH, Kübler HR, von Randenborgh H, Fend F, Pohla H, Breul J, et al. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial. J Gene Med 2007; 9:547 - 60; http://dx.doi.org/10.1002/jgm.1051; PMID: 17514769
   PubMed Web of Science ®Google Scholar
• Pohla H, Frankenberger B, Stadlbauer B, Oberneder R, Hofstetter A, Willimsky G, et al. Allogeneic vaccination for renal cell carcinoma: development and monitoring. Bone Marrow Transplant 2000; 25:Suppl 2 S83 - 7; http://dx.doi.org/10.1038/sj.bmt.1702362; PMID: 10933197
   PubMedGoogle Scholar
• Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanović S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50:213 - 9; http://dx.doi.org/10.1007/s002510050595; PMID: 10602881
   PubMed Web of Science ®Google Scholar
• Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, et al. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 2000; 60:4845 - 9; PMID: 10987296
   PubMed Web of Science ®Google Scholar
• Otto K, Andersen MH, Eggert A, Keikavoussi P, Pedersen LO, Rath JC, et al. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 2005; 23:884 - 9; http://dx.doi.org/10.1016/j.vaccine.2004.08.007; PMID: 15603888
   PubMed Web of Science ®Google Scholar
• Sadovnikova E, Jopling LA, Soo KS, Stauss HJ. Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur J Immunol 1998; 28:193 - 200; http://dx.doi.org/10.1002/(SICI)1521-4141(199801)28:01<193::AID-IMMU193>3.0.CO;2-K; PMID: 9485199
   PubMed Web of Science ®Google Scholar
• Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O, et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 2002; 62:5818 - 27; PMID: 12384544
   PubMed Web of Science ®Google Scholar
• Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998; 101:2290 - 6; http://dx.doi.org/10.1172/JCI488; PMID: 9593785
   PubMed Web of Science ®Google Scholar
• van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17:2257 - 317; http://dx.doi.org/10.1038/sj.leu.2403202; PMID: 14671650
   PubMed Web of Science ®Google Scholar
• Brochet X, Lefranc MP, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 2008; 36:Web Server issue W503-8; http://dx.doi.org/10.1093/nar/gkn316; PMID: 18503082
   PubMedGoogle Scholar
• Lefranc MP, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, Bellahcene F, et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res 2009; 37:Database issue D1006 - 12; http://dx.doi.org/10.1093/nar/gkn838; PMID: 18978023
   PubMed Web of Science ®Google Scholar
• Wieczorek G, Asemissen A, Model F, Turbachova I, Floess S, Liebenberg V, et al. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 2009; 69:599 - 608; http://dx.doi.org/10.1158/0008-5472.CAN-08-2361; PMID: 19147574
   PubMed Web of Science ®Google Scholar